Literature DB >> 23741072

Glioma grade is associated with the accumulation and activity of cells bearing M2 monocyte markers.

Michael Prosniak1, Larry A Harshyne, David W Andrews, Lawrence C Kenyon, Kamila Bedelbaeva, Tatiyana V Apanasovich, Ellen Heber-Katz, Mark T Curtis, Paolo Cotzia, D Craig Hooper.   

Abstract

PURPOSE: This study is directed at identifying the cell source(s) of immunomodulatory cytokines in high-grade gliomas and establishing whether the analysis of associated markers has implications for tumor grading. EXPERIMENTAL
DESIGN: Glioma specimens classified as WHO grade II-IV by histopathology were assessed by gene expression analysis and immunohistochemistry to identify the cells producing interleukin (IL)-10, which was confirmed by flow cytometry and factor secretion in culture. Finally, principal component analysis (PCA) and mixture discriminant analysis (MDA) were used to investigate associations between expressed genes and glioma grade.
RESULTS: The principle source of glioma-associated IL-10 is a cell type that bears phenotype markers consistent with M2 monocytes but does not express all M2-associated genes. Measures of expression of the M2 cell markers CD14, CD68, CD163, and CD204, which are elevated in high-grade gliomas, and the neutrophil/myeloid-derived suppressor cell (MDSC) subset marker CD15, which is reduced, provide the best index of glioma grade.
CONCLUSIONS: Grade II and IV astrocytomas can be clearly differentiated on the basis of the expression of certain M2 markers in tumor tissues, whereas grade III astrocytomas exhibit a range of expression between the lower and higher grade specimens. The content of CD163(+) cells distinguishes grade III astrocytoma subsets with different prognosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23741072     DOI: 10.1158/1078-0432.CCR-12-1940

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  89 in total

Review 1.  The Gut-Brain Axis, Paving the Way to Brain Cancer.

Authors:  Ruty Mehrian-Shai; Juergen K V Reichardt; Curtis C Harris; Amos Toren
Journal:  Trends Cancer       Date:  2019-03-16

Review 2.  Glioblastoma niches: from the concept to the phenotypical reality.

Authors:  Davide Schiffer; Marta Mellai; Enrica Bovio; Ilaria Bisogno; Cristina Casalone; Laura Annovazzi
Journal:  Neurol Sci       Date:  2018-05-08       Impact factor: 3.307

3.  Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment.

Authors:  Wouter B L van den Bossche; Anne Kleijn; Charlotte E Teunissen; Jane S A Voerman; Cristina Teodosio; David P Noske; Jacques J M van Dongen; Clemens M F Dirven; Martine L M Lamfers
Journal:  Neuro Oncol       Date:  2018-10-09       Impact factor: 12.300

4.  CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.

Authors:  Joseph A Flores-Toro; Defang Luo; Adithya Gopinath; Matthew R Sarkisian; James J Campbell; Israel F Charo; Rajinder Singh; Thomas J Schall; Meenal Datta; Rakesh K Jain; Duane A Mitchell; Jeffrey K Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-26       Impact factor: 11.205

5.  CSF1 Overexpression Promotes High-Grade Glioma Formation without Impacting the Polarization Status of Glioma-Associated Microglia and Macrophages.

Authors:  Ishani De; Megan D Steffen; Paul A Clark; Clayton J Patros; Emily Sokn; Stephanie M Bishop; Suzanne Litscher; Vilena I Maklakova; John S Kuo; Fausto J Rodriguez; Lara S Collier
Journal:  Cancer Res       Date:  2016-03-24       Impact factor: 12.701

6.  Absolute quantification of tumor-infiltrating immune cells in high-grade glioma identifies prognostic and radiomics values.

Authors:  A Reum Kim; Kyu Sung Choi; Min-Sung Kim; Kyung-Min Kim; Ho Kang; Sojin Kim; Tamrin Chowdhury; Hyeon Jong Yu; Chae Eun Lee; Joo Ho Lee; Soon-Tae Lee; Jae Kyung Won; Jin Wook Kim; Yong-Hwy Kim; Tae Min Kim; Sung-Hye Park; Seung Hong Choi; Eui-Cheol Shin; Chul-Kee Park
Journal:  Cancer Immunol Immunother       Date:  2021-01-08       Impact factor: 6.968

Review 7.  Microenvironmental clues for glioma immunotherapy.

Authors:  Michael Platten; Katharina Ochs; Dieter Lemke; Christiane Opitz; Wolfgang Wick
Journal:  Curr Neurol Neurosci Rep       Date:  2014-04       Impact factor: 5.081

8.  Serum exosomes and cytokines promote a T-helper cell type 2 environment in the peripheral blood of glioblastoma patients.

Authors:  Larry A Harshyne; Brian J Nasca; Lawrence C Kenyon; David W Andrews; D Craig Hooper
Journal:  Neuro Oncol       Date:  2015-07-14       Impact factor: 12.300

9.  Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype.

Authors:  Konrad Gabrusiewicz; Benjamin Rodriguez; Jun Wei; Yuuri Hashimoto; Luke M Healy; Sourindra N Maiti; Ginu Thomas; Shouhao Zhou; Qianghu Wang; Ahmed Elakkad; Brandon D Liebelt; Nasser K Yaghi; Ravesanker Ezhilarasan; Neal Huang; Jeffrey S Weinberg; Sujit S Prabhu; Ganesh Rao; Raymond Sawaya; Lauren A Langford; Janet M Bruner; Gregory N Fuller; Amit Bar-Or; Wei Li; Rivka R Colen; Michael A Curran; Krishna P Bhat; Jack P Antel; Laurence J Cooper; Erik P Sulman; Amy B Heimberger
Journal:  JCI Insight       Date:  2016-02-25

10.  1p/19q co-deletion status is associated with distinct tumor-associated macrophage infiltration in IDH mutated lower-grade gliomas.

Authors:  Yanyu Zhang; Yuan Xie; Liqun He; Jiefu Tang; Qiyuan He; Qingze Cao; Langjun Cui; Wei Guo; Kai Hua; Anna Dimberg; Liang Wang; Lei Zhang
Journal:  Cell Oncol (Dordr)       Date:  2020-09-11       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.